Elicio Therapeutics Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company, reported its financial results for the third quarter ended September 30, 2025, and provided recent corporate and clinical updates. The company's current cash position is expected to support operations beyond the anticipated Phase 2 AMPLIFY-7P event-driven primary disease-free survival $(DFS)$ endpoint analysis, now expected in the first half of 2026. Since the beginning of Q3 2025, Elicio has raised approximately $11.1 million through its at-the-market program, extending its cash runway through the second quarter of 2026. In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma, fewer disease progressions and deaths than projected have been observed as of November 6, 2025. The company remains blinded to clinical efficacy outcomes. Based on 2:1 randomization, Elicio believes the lower-than-projected number of events may reflect a favorable impact on DFS. Research and development expenses for Q3 2025 were $5.0 million, compared to $7.2 million in the same period of the prior year. Elicio's total liabilities and stockholders' equity were reported as $28.3 million as of the end of the quarter. The company also noted that the Independent Data Monitoring Committee recommended the continuation of the ELI-002 7P Phase 2 study without modifications and confirmed a favorable safety profile as of August 2025. Upon reaching the primary DFS endpoint, Elicio plans to request an End of Phase 2 meeting with the U.S. FDA to finalize the Phase 3 study design for ELI-002 7P.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9575449-en) on November 13, 2025, and is solely responsible for the information contained therein.
Comments